Bypass of genetic constraints during mutator evolution to antibiotic resistance

Proceedings of the Royal Society B: Biological Sciences

Volumn 282, Issue 1804, 2015, Pages

  Couce, Alejandro ^a,b   Rodríguez Rojas, Alexandro ^a,c   Blázquez, Jesús ^a,d  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Epistasis; Mutational pathways; Mutator; PBP3; TEM 1

Indexed keywords

ANTIBIOTIC RESISTANCE; ENZYME ACTIVITY; EVOLUTIONARY BIOLOGY; GENETIC VARIATION; GENOTYPE; MICROBIAL ACTIVITY; MUTATION; NATURAL SELECTION;

ESCHERICHIA COLI;

ANTIINFECTIVE AGENT; CEFOTAXIME; ESCHERICHIA COLI PROTEIN; INORGANIC PYROPHOSPHATASE; MUTT PROTEIN, E COLI;

ALLELE; ANTIBIOTIC RESISTANCE; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG EFFECTS; ESCHERICHIA COLI; GENETICS; METABOLISM; MOLECULAR EVOLUTION; MUTATION;

ALLELES; ANTI-BACTERIAL AGENTS; CEFOTAXIME; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; EVOLUTION, MOLECULAR; MODELS, GENETIC; MUTATION; PYROPHOSPHATASES;

EID: 84923361032     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2014.2698     Document Type: Article

References (69)

1. De Visser JAGM, Cooper TF, Elena SF. 2011 The causes of epistasis. Proc. R. Soc. B 278, 3617-3624. (doi:10.1098/rspb.2011.1537).
2. Weinreich DM, Watson RA, Chao L. 2005 Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. Evol. Int. J. Org. Evol. 59, 1165-1174. (doi:10.1111/j.0014-3820.2005. tb01769.x).
3. Bridgham JT, Carroll SM, Thornton JW. 2006 Evolution of hormone-receptor complexity by molecular exploitation. Science 312, 97-101. (doi:10.1126/science.1123348).
4. Franke J, Klozer A, de Visser JAGM, Krug J. 2011 Evolutionary accessibility of mutational pathways. PLoS Comput. Biol. 7, 1002134. (doi:10.1371/ journal.pcbi.1002134).
5. Kvitek DJ, Sherlock G. 2011 Reciprocal sign epistasis between frequently experimentally evolved adaptive mutations causes a rugged fitness landscape. PLoS Genet. 7, 1002056. (doi:10.1371/journal. pgen.1002056).
6. Lalic J, Elena SF. 2012 Magnitude and sign epistasis among deleterious mutations in a positive-sense plant RNA virus. Heredity 109, 71-77. (doi:10.1038/hdy.2012.15).
7. Salverda MLM, Dellus E, Gorter FA, Debets AJM, van der Oost J, Hoekstra RF, Tawfik DS, de Visser JAGM. 2011 Initial mutations direct alternative pathways of protein evolution. PLoS Genet. 7, 1001321. (doi:10.1371/journal.pgen.1001321).
8. Weinreich DM, Delaney NF, Depristo MA, Hartl DL. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312, 111-114. (doi:10.1126/science.1123539).
9. Poelwijk FJ, Tanase-Nicola S, Kiviet DJ, Tans SJ. Reciprocal sign epistasis is a necessary condition for multi-peaked fitness landscapes. J. Theor. Biol. 272, 141-144. (doi:10.1016/j.jtbi.2010.12.015).
10. Stern DL. 2013 The genetic causes of convergent evolution. Nat. Rev. Genet. 14, 751-764. (doi:10.1038/nrg3483).
11. de Visser JAGM, Krug J. 2014 Empirical fitness landscapes and the predictability of evolution. Nat. Rev. Genet. 15, 480-490. (doi:10.1038/nrg3744).
12. LeClerc JE, Li B, Payne WL, Cebula TA. 1996 High mutation frequencies among Escherichia coli and salmonella pathogens. Science 274, 1208-1211. (doi:10.1126/science.274.5290.1208).
13. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000 High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251-1253. (doi:10.1126/science.288.5469.1251).
14. Sniegowski PD, Gerrish PJ, Lenski RE. 1997 Evolution of high mutation rates in experimental populations of E. coli. Nature 387, 703-705. (doi:10.1038/42701).
15. Pal C, Macia MD, Oliver A, Schachar I, Buckling A. Coevolution with viruses drives the evolution of bacterial mutation rates. Nature 450, 1079-1081. (doi:10.1038/nature06350).
16. Notley-McRobb L, Pinto R, Seeto S, Ferenci T. 2002 Regulation of mutY and nature of mutator mutations in Escherichia coli populations under nutrient limitation. J. Bacteriol. 184, 739-745. (doi:10.1128/JB.184.3.739-745.2002).
17. Tenaillon O, Toupance B, Nagard HL, Taddei F, Godelle B. 1999 Mutators, population size, adaptive landscape and the adaptation of asexual populations of bacteria. Genetics 152, 485-493.
18. Canfield GS, Schwingel JM, Foley MH, Vore KL, Boonanantanasarn K, Gill AL, Sutton MD, Gill SR. 2013 Evolution in fast forward: A potential role for mutators in accelerating Staphylococcus aureus pathoadaptation. J. Bacteriol. 195, 615-628. (doi:10.1128/JB.00733-12).
19. Rodriguez-Rojas A, Couce A, Blazquez J. 2010 Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonasaeruginosa. Antimicrob. Agents Chemother. 54, 4948-4949. (doi:10.1128/AAC.00415-10).
20. Perron GG, Hall AR, Buckling A. 2010 Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. Am. Nat. 176, 303-311. (doi:10.1086/655217).
21. Miller JH. 1996 Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu. Rev. Microbiol. 50, 625-643. (doi:10.1146/ annurev.micro.50.1.625).
22. Couce A, Guelfo JR, Blazquez J. 2013 Mutational spectrum drives the rise of mutator bacteria. PLoS Genet. 9, 1003167. (doi:10.1371/journal.pgen.1003167).
23. Lindgren PK, Marcusson LL, Sandvang D, Frimodt- M0ller N, Hughes D. 2005 Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob. Agents Chemother. 49, 2343-2351. (doi:10.1128/AAC.49.6.2343-2351.2005).
24. Salverda MLM, De Visser JAGM, Barlow M. 2010 Natural evolution of TEM-1 b-lactamase: Experimental reconstruction and clinical relevance. FEMS Microbiol. Rev. 34,1015-1036. (doi:10.1111/j.1574-6976.2010.00222.x).
25. Blazquez J, Morosini MI, Negri MC, Baquero F. 2000 Selection of naturally occurring extended-spectrum TEM beta-lactamase variants by fluctuating beta- lactam pressure. Antimicrob. Agents Chemother. 2182-2184. (doi:10.1128/AAC.44.8.2182-2184.2000).
26. Schenk MF, Szendro IG, Krug J, De Visser JAGM. Quantifying the adaptive potential of an antibiotic resistance enzyme. PLoS Genet. 8, 1002783. (doi:10.1371/journal.pgen.1002783).
27. Schenk MF, Szendro IG, Salverda MLM, Krug J, de Visser JAGM. 2013 Patterns of epistasis between beneficial mutations in an antibiotic resistance gene. Mol. Biol. Evol. 30,1779-1787. (doi:10.1093/molbev/mst096).
28. Denamur E, Matic I. 2006 Evolution of mutation rates in bacteria. Mol. Microbiol. 60, 820-827. (doi:10.1111/j.1365-2958.2006.05150.x).
29. Covarrubias L, Cervantes L, Covarrubias A, Soberoan X, Vichido I, Blanco A, Kupersztoch-Portnoy YM, Bolivar F. 1981 Construction and characterization of new cloning vehicles. V. Mobilization and coding properties of pBR322 and several deletion derivatives including pBR327 and pBR328. Gene 13, 25-35. (doi:10.1016/0378-1119(81)90040-8).
30. Cupples CG, Miller JH. 1989 A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc. Natl Acad. Sci. USA 86, 5345-5349. (doi:10.1073/pnas.86.14.5345).
31. Seier T, Padgett DR, Zilberberg G, Sutera VA, Toha N, Lovett ST. 2011 Insights into mutagenesis using Escherichia coli chromosomal lacZ strains that enable detection of a wide spectrum of mutational events. Genetics 188, 247-262. (doi:10.1534/genetics.111.127746).
32. Lovett ST, Hurley RL, Sutera VA, Aubuchon RH, Lebedeva MA. 2002 Crossing over between regions of limited homology in Escherichia coli: RecA- dependent and RecA-independent pathways. Genetics 160, 851-859.
33. Vidmar JJ, Cupples CG. 1993 MutY repair is mutagenic in mutT- strains of Escherichia coli. Can. J. Microbiol. 39, 892-894. (doi:10.1139/m93-133).
34. Poole K. 2004 Resistance to beta-lactam antibiotics. Cell. Mol. Life Sci. 61, 2200-2223. (doi:10.1007/s00018-004-4060-9).
35. Okusu H, Ma D, Nikaido H. 1996 AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- resistance (Mar) mutants. J. Bacteriol. 178, 306-308.
36. Nikaido H, Rosenberg EY, Foulds J. 1983 Porin channels in Escherichia coli: Studies with beta-lactams in intact cells. J. Bacteriol. 153, 232-240.
37. Davin-Regli A, Bolla J-M, James C, Lavigne J-P, Chevalier J, Garnotel E, Molitor A, Pages J-M. 2008 Membrane permeability and regulation of drug 'influx and efflux' in enterobacterial pathogens. Curr. Drug Targets 9, 750-759. (doi:10.2174/138945008785747824).
38. Nishino K, Yamaguchi A. 2001 Analysis of a complete library of putative drug transporter genes in Escherichia coli. J. Bacteriol. 183, 5803-5812. (doi:10.1128/JB.183.20.5803-5812.2001).
39. Yu EW, Aires JR, McDermott G, Nikaido H. 2005 A periplasmic drug-binding site of the acrb multidrug efflux pump: A crystallographic and site-directed mutagenesis study. J. Bacteriol. 187, 6804-6815. (doi:10.1128/JB.187.19.6804-6815.2005).
40. Vaara M. 1993 Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrob. Agents Chemother. 37, 2255-2260. (doi:10.1128/AAC.37.11.2255).
41. Orencia MC, Yoon JS, Ness JE, Stemmer WP, Stevens RC. 2001 Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. 8, 238-242. (doi:10.1038/84981).
42. Hedge PJ, Spratt BG. 1985 Resistance to beta- lactam antibiotics by re-modelling the active site of an E. coli penicillin-binding protein. Nature 318, 478-480. (doi:10.1038/318478a0).
43. Hedge PJ, Spratt BG. 1985 Amino acid substitutions that reduce the affinity of penicillin-binding protein of Escherichia coli for cephalexin. Eur. J. Biochem. FEBS 151, 111-121. (doi:10.1111/j.1432-1033.1985.tb09075.x).
44. Sun S, Selmer M, Andersson DI. 2014 Resistance to b-lactam antibiotics conferred by point mutations in penicillin-binding proteins PBP3, PBP4 and PBP6 in Salmonella enterica. PLoS ONE 9, 97202. (doi:10.1371/journal.pone.0097202).
45. Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M. 2001 Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase- negative ampicillin-resistant Haemophilus influenzae. Antimicrob. Agents Chemother. 45, 1693-1699. (doi:10.1128/AAC.45.6.1693-1699.2001).
46. Nguyen-Disteche M, Fraipont C, Buddelmeijer N, Nanninga N. 1998 The structure and function of Escherichia coli penicillin-binding protein 3. Cell. Mol. Life Sci. 54, 309-316. (doi:10.1007/s000180050157).
47. Tavio MM, Aquili VD, Vila J, Poveda JB. 2013 Resistance to ceftazidime in Escherichia coli associated with AcrR, MarR, and PBP3 mutations and overexpression of sdiA. J. Med. Microbiol. 63, 56-65. (doi:10.1099/jmm.0.063727-0).
48. Efron B, Thisted R. 1976 Estimating the number of unseen species: How many words did Shakespeare know? Biometrika 63, 435-447. (doi:10.2307/2335721).
49. Dabernat H, Delmas C, Seguy M, Pelissier R, Faucon G, Bennamani S, Pasquier C. 2002. Diversity of b-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob. Agents Chemother 46, 2208-2218. (doi:10.1128/AAC.46.7.2208-2218.2002).
50. Weigand MR, Sundin GW. 2012 General and inducible hypermutation facilitate parallel adaptation in Pseudomonas aeruginosa despite divergent mutation spectra. Proc. Natl Acad. Sci. USA 109,13 68013 685. (doi:10.1073/pnas.1205357109).
51. Dettman JR, Rodrigue N, Melnyk AH, Wong A, Bailey SF, Kassen R. 2012 Evolutionary insight from whole-genome sequencing of experimentally evolved microbes. Mol. Ecol. 21, 2058-2077. (doi:10.1111/j.1365-294X.2012.05484.x).
52. Tenaillon O, Rodriguez-Verdugo A, Gaut RL, Mc Donald P, Bennett AF, Long AD, Gaut BS. 2012 The molecular diversity of adaptive convergence. Science 335, 457-461. (doi:10.1126/science.1212986).
53. Albert TJ et al. 2005 Mutation discovery in bacterial genomes: Metronidazole resistance in Helicobacter pylori. Nat. Methods 2, 951-953. (doi:10.1038/nmeth805).
54. Toprak E, Veres A, Michel J-B, Chait R, Hartl DL, Kishony R. 2012 Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 44, 101-105. (doi:10.1038/ng.1034).
55. Wong A, Rodrigue N, Kassen R. 2012 Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Genet. 8, 1002928. (doi:10.1371/journal.pgen.1002928).
56. Maharjan RP, Ferenci T. 2013 Epistatic interactions determine the mutational pathways and coexistence of lineages in clonal Escherichia coli populations. Evolution 67, 2762-2768. (doi:10.1111/evo.12137).
57. Lunzer M, Miller SP, Felsheim R, Dean AM. 2005 The biochemical architecture of an ancient adaptive landscape. Science 310, 499-501. (doi:10.1126/science.1115649).
58. da Silva J, Coetzer M, Nedellec R, Pastore C, Mosier DE. 2010 Fitness epistasis and constraints onadaptation in a human immunodeficiency virus type 1 protein region. Genetics 185, 293-303. (doi:10.1534/genetics.109.112458).
59. Gavrilets S. 1997 Evolution and speciation on holey adaptive landscapes. Trends Ecol. Evol. 12, 312. (doi:10.1016/S0169-5347(97)01098-7).
60. Poyart C, Mugnier P, Quesne G, Berche P, Trieu-Cuot P. 1998 A novel extended-spectrum TEM-type b-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 42, 108-113.
61. Barlow M, Fatollahi J, Salverda M. 2009 Evidence for recombination among the alleles encoding TEM and SHV b-lactamases. J. Antimicrob. Chemother. 63, 256-259. (doi:10.1093/jac/dkn475).
62. Pozzi C et al. 2012 Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog. 8, 1002626. (doi:10.1371/journal.ppat.1002626).
63. Okabe T, Yamazaki Y, Shiotani M, Suzuki T, Shiohara M, Kasuga E, Notake S, Yanagisawa H. 2010 An amino acid substitution in PBP-3 in Haemophilus influenzae associate with the invasion to bronchial epithelial cells. Microbiol. Res. 165,11-20. (doi:10.1016/j.micres.2008.03.003).
64. Blaazquez J. 2003 Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 37, 1201-1209. (doi:10.1086/378810).
65. Baba T et al. 2006 Construction of Escherichia coli K- 12 in-frame, single-gene knockout mutants: the Keio collection. Mol. Syst. Biol. 2, 2006-2008. (doi:10.1038/msb4100050).
66. Miller JH. 1992 A short course in bacterial genetics: a laboratory manual and handbook for Escherichia Coli and related bacteria. New York, NY: CSHL Press.
67. Hegreness M, Shoresh N, Hartl D, Kishony R. 2006 An equivalence principle for the incorporation of favorable mutations in asexual populations. Science 311, 1615-1617.(doi:10.1126/science.1122469).
68. Lee SW, Edlin G. 1985 Expression of tetracycline resistance in pBR322 derivatives reduces the reproductive fitness of plasmid-containing Escherichia coli. Gene 39, 173-180. (doi:10.1016/0378-1119(85)90311-7).
69. Datta DB, Arden B, Henning U. 1977 Major proteins of the Escherichia coli outer cell envelope membrane as bacteriophage receptors. J. Bacteriol. 131, 821-829.